期刊
NATURE COMMUNICATIONS
卷 5, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms6245
关键词
-
资金
- Parkinson's UK [G-0813]
- Wellcome Trust [078662, GR077544AIA]
- MRC [MR/K005146/1, G0501573]
- Wellcome/MRC Parkinson's Disease Consortium
- University of Sheffield
- MRC Protein Phosphorylation Unit at the University of Dundee [WT089698]
- ERC Starting Grant [309742]
- Wolfson Foundation
- MRC [MR/K005146/1, MC_G1000735, G0501573] Funding Source: UKRI
- Medical Research Council [G0501573, MR/K005146/1, MC_G1000735] Funding Source: researchfish
- Parkinson's UK [G-0813] Funding Source: researchfish
- European Research Council (ERC) [309742] Funding Source: European Research Council (ERC)
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common genetic cause of Parkinson's disease. LRRK2 is a multifunctional protein affecting many cellular processes and has been described to bind microtubules. Defective microtubule-based axonal transport is hypothesized to contribute to Parkinson's disease, but whether LRRK2 mutations affect this process to mediate pathogenesis is not known. Here we find that LRRK2 containing pathogenic Roc-COR domain mutations (R1441C, Y1699C) preferentially associates with deacetylated microtubules, and inhibits axonal transport in primary neurons and in Drosophila, causing locomotor deficits in vivo. In vitro, increasing microtubule acetylation using deacetylase inhibitors or the tubulin acetylase alpha TAT1 prevents association of mutant LRRK2 with microtubules, and the deacetylase inhibitor trichostatin A (TSA) restores axonal transport. In vivo knockdown of the deacetylases HDAC6 and Sirt2, or administration of TSA rescues both axonal transport and locomotor behavior. Thus, this study reveals a pathogenic mechanism and a potential intervention for Parkinson's disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据